Alzheimer's Disease and microRNA-132: A Widespread Pathological Factor and Potential Therapeutic Target.

Frontiers in Neuroscience
Meng Zhang, Zhigang Bian

Abstract

Alzheimer's disease (AD) is a common neurodegenerative disease in the elderly and is the most common type of dementia. AD is mostly gradual onset, and involves slow, progressive mental decline, accompanied by personality changes; the incidence of AD gradually increases with age. The etiology of AD is unknown, although it is currently believed to be related to abnormal deposition of amyloid β-protein (Aβ) in the brain, hyperphosphorylation of microtubule-associated protein tau, and the release of various cytokines, complements, activators and chemokines by cells. MicroRNAs (miRNAs) are a class of highly conserved non-coding RNAs that regulate gene expression at the post-transcriptional level, and manipulate the functions of intracellular proteins and physiological processes. Emerging studies have shown that miRNA plays an important role in regulating AD-related genes. MiR-132 is known as "NeurimmiR" due to its involvement in numerous neurophysiological and pathological processes. Accumulating pre-clinical results suggest that miR-132 may be involved in the progression of Aβ and tau pathology. Moreover, clinical studies have indicated that decreased circulating miR-132 levels could be used a potential diagnostic biomarker in AD. ...Continue Reading

References

Dec 2, 1993·Nature·C KenyonR Tabtiang
May 15, 2002·Current Biology : CB·Mariana Lagos-QuintanaThomas Tuschl
Apr 4, 2003·The New England Journal of Medicine·Barry ReisbergUNKNOWN Memantine Study Group
Apr 28, 2007·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·G Sorrentino, V Bonavita
Nov 13, 2007·Nature Neuroscience·Matthew E KleinRichard H Goodman
Dec 18, 2007·Cell·Beth StevensBen A Barres
Apr 25, 2008·Proceedings of the National Academy of Sciences of the United States of America·Sébastien S HébertBart De Strooper
Oct 29, 2008·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Keiji Itaka, Kazunori Kataoka
Oct 13, 2009·Molecular Endocrinology·Jay C StrumK Michelle Waters
Apr 24, 2010·Journal of Alzheimer's Disease : JAD·Peter T Nelson, Wang-Xia Wang
Aug 4, 2010·Current Alzheimer Research·K IqbalI Grundke-Iqbal
Aug 21, 2010·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·Eija PöllänenVuokko Kovanen
Nov 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Stephen T MagillRichard H Goodman
Aug 3, 2011·Human Molecular Genetics·Pascal Y SmithSébastien S Hébert
Dec 26, 2012·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Cyndy B CordellUNKNOWN Medicare Detection of Cognitive Impairment Workgroup
Jul 5, 2013·Frontiers in Genetics·A TurchinovichB Burwinkel
Sep 10, 2013·EMBO Molecular Medicine·Pierre LauBart De Strooper
Sep 12, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Zhentao ZhangKeqiang Ye
Sep 17, 2013·Journal of Neurochemistry·John R DicksonMichael S Wolfe
Oct 4, 2013·Aging·Nicole Noren HootenMichele K Evans
Oct 29, 2013·Nature Neuroscience·Allison R Bialas, Beth Stevens
Feb 5, 2014·Nature Reviews. Clinical Oncology·Heidi SchwarzenbachKlaus Pantel
Feb 27, 2014·Frontiers in Molecular Neuroscience·Philipp FollertChristophe Béclin
Aug 20, 2014·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Neil R Smalheiser
Dec 3, 2014·Advanced Drug Delivery Reviews·Huiyuan WangYongzhuo Huang
Dec 17, 2014·Future Medicinal Chemistry·Volker Baumann, Johannes Winkler
Jan 16, 2015·Journal of Alzheimer's Disease : JAD·Michael A WilliamsGiuliana Silvestri
Jan 16, 2015·Journal of Alzheimer's Disease : JAD·Bing XieShunjiang Xu
Jan 28, 2015·Journal of Alzheimer's Disease : JAD·Doo Young LeeKon Chu
Mar 26, 2015·Frontiers in Neurology·Guy BarryCynthia Shannon Weickert
May 20, 2015·Frontiers in Aging Neuroscience·Juhyun Song, Jong Eun Lee
May 23, 2015·Frontiers in Aging Neuroscience·Selva Rivas-ArancibiaMaría Sepúlveda-Parada
Sep 13, 2015·Human Molecular Genetics·Pascal Y SmithSébastien S Hébert
Oct 28, 2015·Clinica Chimica Acta; International Journal of Clinical Chemistry·Arpna SrivastavaP Sarat Chandra
Jan 17, 2016·Learning & Memory·Katelin F HansenKarl Obrietan
Mar 26, 2016·Frontiers in Molecular Neuroscience·Olena LykhmusMaryna Skok
Aug 4, 2016·EMBO Molecular Medicine·Evgenia SaltaBart De Strooper
Nov 7, 2016·Neurobiology of Aging·Sabrina PichlerMatthias Riemenschneider
Dec 8, 2016·Methods in Molecular Biology·Kim A LennoxMark A Behlke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: RNA Regulation

RNA regulation involves several mechanisms that are used by cells to decrease or increase the production of RNA. Disruption of RNA regulatory processes has been associated with Alzheimer's disease (AD). Here are the latest discoveries pertaining to RNA regulation and AD.